TY - JOUR
T1 - Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers
AU - Sade, Revital Bruchim Bar
AU - Chetrit, Angela
AU - Figer, Arie
AU - Papa, Moshe Z.
AU - Flex, Dov
AU - Rizel, Shulamit
AU - Friedman, Eitan
N1 - Funding Information:
This study was performed in part by a grant support to Eitan Friedman from the Tel-Aviv University, and in partial fulfillment of the requirements for a PhD degree to Revital Bruchim Bar-Sade, at the Department of Human Genetics, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
PY - 2006/3
Y1 - 2006/3
N2 - The aim of this study was to compare reproductive factors, use of oral contraceptives (OC) and hormone replacement therapy (HRT) in consecutive Jewish Ashkenazi breast cancer patients, with and without BRCA1/BRCA2 mutations. Jewish Israeli women with breast cancer (n = 385) were genotyped for the three predominant Jewish mutations in BRCA1 and BRCA2, and data on reproductive factors, OC and HRT use, were analyzed using logistic regression analyses. Overall, 28/385 (7.3%) of participants were mutation carriers, the majority of whom were Ashkenazi (n = 22; 78.6%) and were diagnosed with breast cancer at or under age 49 years (n = 18; 64.3%). Mutation carriers were more likely than non-carriers to ever use OC (39.3% vs. 20.2%; P = 0.053), HRT (35.7% vs. 13.7%; P = 0.007), and have first menarche at or below 12 years of age (71.4% vs. 40.6%; P = 0.03). Multivariate analysis showed that Ashkenazi women diagnosed with breast cancer under 40 years of age, with a family history of breast/ovarian cancer, who ever used HRT were more likely to be mutation carriers. This study has shown that HRT use is more prevalent among Jewish Ashkenazi mutation carriers, but its role in modifying breast cancer risk in mutation carriers remains unknown.
AB - The aim of this study was to compare reproductive factors, use of oral contraceptives (OC) and hormone replacement therapy (HRT) in consecutive Jewish Ashkenazi breast cancer patients, with and without BRCA1/BRCA2 mutations. Jewish Israeli women with breast cancer (n = 385) were genotyped for the three predominant Jewish mutations in BRCA1 and BRCA2, and data on reproductive factors, OC and HRT use, were analyzed using logistic regression analyses. Overall, 28/385 (7.3%) of participants were mutation carriers, the majority of whom were Ashkenazi (n = 22; 78.6%) and were diagnosed with breast cancer at or under age 49 years (n = 18; 64.3%). Mutation carriers were more likely than non-carriers to ever use OC (39.3% vs. 20.2%; P = 0.053), HRT (35.7% vs. 13.7%; P = 0.007), and have first menarche at or below 12 years of age (71.4% vs. 40.6%; P = 0.03). Multivariate analysis showed that Ashkenazi women diagnosed with breast cancer under 40 years of age, with a family history of breast/ovarian cancer, who ever used HRT were more likely to be mutation carriers. This study has shown that HRT use is more prevalent among Jewish Ashkenazi mutation carriers, but its role in modifying breast cancer risk in mutation carriers remains unknown.
KW - BRCA1/2 germline mutations
KW - Breast cancer
KW - HRT and OC use
KW - Reproductive factors
UR - http://www.scopus.com/inward/record.url?scp=33644780764&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2005.08.045
DO - 10.1016/j.ejca.2005.08.045
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 16464572
AN - SCOPUS:33644780764
VL - 42
SP - 650
EP - 655
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 5
ER -
